CURE1d
Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
The American Journal of Managed Care7d
Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...
BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
The Manila Times1d
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of ...
BioSpace3d
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
BioInvent International: BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma
LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...
Pharmabiz3d
China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer
China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...
Physician's Weekly5d
Therapeutic effect of formononetin in 6-OHDA induced Parkinson disease in rats.
Preclinical models of Parkinson's disease (PD) have been developed using intracerebroventricular (i.c.v.) injection of 6-hydroxydopamine (6-OHDA) to induce neurodegeneration and motor dysfunction.